Balaxi Pharma

Why is Balaxi Pharmaceuticals Ltd falling/rising?

As of 31-Aug, Balaxi Pharmaceuticals Ltd's stock price is at 22.34, reflecting a 0.89% decrease and significant underperformance compared to the Sensex. The stock has declined 16.86% year-to-date and 51.28% over the past year, indicating a bearish trend with reduced investor interest.

As of 31-Aug, Balaxi Pharmaceuticals Ltd's stock price is falling, currently at 22.34, which reflects a decrease of 0.2 or 0.89%. The stock has underperformed compared to the benchmark Sensex, with a performance today that is 0.49% lower than the sector average. Over the past week, the stock has declined by 2.06%, and it has shown significant losses over longer periods, including a 16.86% drop year-to-date and a staggering 51.28% decline over the past year.<BR><BR>Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Investor participation has also decreased, with delivery volume falling by 36.1% compared to the 5-day average, suggesting reduced interest in trading the stock. Overall, these factors contribute to the downward movement of Balaxi Pharmaceuticals Ltd's stock price.

Who are in the management team of Balaxi Pharma?

The management team of Balaxi Pharma includes Ashish Maheshwari (Chairman/Executive Director), Minoshi Maheshwari (Non Executive Director), and five Independent Non Executive Directors: Kunal M Bhakta, Gandhi Gamji, M. Srinivas Rao, and Purnima Singh Kamble.

The management team of Balaxi Pharma includes the following individuals:<BR><BR>1. **Ashish Maheshwari** - Chairman / Executive Director<BR>2. **Minoshi Maheshwari** - Non Executive Director<BR>3. **Kunal M Bhakta** - Independent Non Executive Director<BR>4. **Gandhi Gamji** - Independent Non Executive Director<BR>5. **M. Srinivas Rao** - Independent Non Executive Director<BR>6. **Purnima Singh Kamble** - Independent Non Executive Director<BR><BR>If you have any more questions about Balaxi Pharma or its operations, feel free to ask!

What does Balaxi Pharma do?

Balaxi Pharmaceuticals Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reported net sales of 81 Cr and a net profit of 1 Cr for June 2026. The company, originally founded in 1942, has a market cap of INR 124 Cr and key financial metrics include a P/E ratio of 51.00 and a debt-equity ratio of 0.23.

Overview: <BR>Balaxi Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in 1942 under the name 'The Anandam Rubber Company Limited' and changed its name to 'Balaxi Ventures Limited' on August 8, 2017. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 81 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 124 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 51.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.23 <BR>Return on Equity: 0.57% <BR>Price to Book: 0.50 <BR><BR>Contact Details: <BR>Address: 41/298-D2 2nd Flr Saniya Plaza, Mahakavi Bharatiyar Road Cochin Kerala : 682035 <BR>Tel: 91-484-4032952/6596725 <BR>Email: secretarial@anandamrubberco.com <BR>Website: http://www.balaxipharma.in

Who are the peers of the Balaxi Pharma?

Balaxi Pharma's peers include Bal Pharma, Alpa Laboratorie, Krebs Biochem, Vaishali Pharma, Lactose (India), Makers Labs, Pharmaids Pharma, Kimia Bioscien, and Tyche Industries. Management risk varies from excellent at Balaxi Pharma and Tyche Industries to below average at several others, with Balaxi Pharma showing excellent growth and capital structure, while its 1-year return is -51.28%.

Peers: The peers of Balaxi Pharma are Bal Pharma, Alpa Laboratorie, Krebs Biochem, Vaishali Pharma, Lactose (India), Makers Labs., Pharmaids Pharma, Kimia Bioscien., and Tyche Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at Balaxi Pharma and Tyche Industries, while Average management risk is found at Bal Pharma, Alpa Laboratorie, and the rest. Below Average management risk is noted at Vaishali Pharma, Lactose (India), Makers Labs., Pharmaids Pharma, and Kimia Bioscien. Growth is rated as Excellent at Balaxi Pharma, Below Average at Bal Pharma, Alpa Laboratorie, Vaishali Pharma, Makers Labs., Pharmaids Pharma, Kimia Bioscien., and the rest, and Good at Lactose (India). Capital Structure is rated as Excellent at Balaxi Pharma and Tyche Industries, Good at Alpa Laboratorie, and Below Average at Bal Pharma, Vaishali Pharma, Lactose (India), Makers Labs., Pharmaids Pharma, and Kimia Bioscien.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Krebs Biochem at -21.00%, while the peer with the lowest is Alpa Laboratorie at -33.58%. Balaxi Pharma's 1-year return is -51.28%, which is lower than both. Additionally, Lactose (India), Makers Labs., Pharmaids Pharma, Kimia Bioscien., and Tyche Industries have a six-month return of 0.00%.

How big is Balaxi Pharma?

As of 31st August, Balaxi Pharmaceuticals Ltd has a market capitalization of 124.00 Cr, with net sales of 280.11 Cr and a net profit of 2.43 Cr for the latest four quarters. The company reported shareholder's funds of 231.74 Cr and total assets of 310.34 Cr as of March 2025.

As of 31st August, Balaxi Pharmaceuticals Ltd has a market capitalization of 124.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, Balaxi Pharmaceuticals reported net sales of 280.11 Cr and a net profit of 2.43 Cr.<BR><BR>As of the latest annual period in March 2025, the company had shareholder's funds amounting to 231.74 Cr and total assets of 310.34 Cr.

Which are the latest news on Balaxi Pharma?

Are Balaxi Pharmaceuticals Ltd latest results good or bad?

Balaxi Pharmaceuticals Ltd's latest results show a significant net profit increase of 348.28% and 14.05% revenue growth, but ongoing challenges with profitability and a 48.79% stock decline over the past year suggest caution for investors. The company's high valuation and low advisory score indicate skepticism about its future prospects.

Balaxi Pharmaceuticals Ltd's latest results present a mixed picture. On one hand, the company reported a significant year-over-year increase in net profit of 348.28% for Q1 FY27, reaching ₹1.30 crore, and a revenue growth of 14.05%, which is a positive sign. The operating profit margin, however, remains under pressure at 5.78%, indicating challenges in translating revenue growth into sustainable profitability.<BR><BR>Despite these improvements, the overall context is concerning. The stock has seen a dramatic decline of 48.79% over the past year, and it currently trades at a high price-to-earnings ratio of 94 times, which raises questions about its valuation relative to its financial performance. The company has also faced deteriorating profitability metrics and a negative long-term growth trajectory, with a five-year EBIT CAGR of -27.00%.<BR><BR>Investor sentiment appears to be cautious, as reflected by the company's low advisory score of 21 out of 100, indicating a "Strong Sell" recommendation. Additionally, there has been a significant exit of institutional investors, which further underscores the skepticism surrounding the company's future prospects.<BR><BR>In summary, while there are signs of recovery in the latest quarter, the broader financial challenges and market sentiment suggest that investors should approach Balaxi Pharmaceuticals with caution.

Should I buy, sell or hold Balaxi Pharmaceuticals Ltd?

Is Balaxi Pharma overvalued or undervalued?

As of November 27, 2025, Balaxi Pharma is considered very attractive and undervalued with a PE ratio of 14.36, significantly lower than its peers like Bajaj Finance and Bajaj Finserv, despite a 53.22% decline in stock performance over the past year.

As of 27 November 2025, Balaxi Pharma's valuation grade has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, with a PE ratio of 14.36, an EV to EBIT of 11.30, and an EV to EBITDA of 10.33. These ratios suggest that Balaxi Pharma is trading at a lower valuation compared to its peers, particularly when compared to Bajaj Finance, which has a PE ratio of 35.15, and Bajaj Finserv, with a PE ratio of 34.78.<BR><BR>In the context of its industry, Balaxi Pharma's Price to Book Value stands at 0.87, which further reinforces its undervaluation relative to competitors like Life Insurance, which has a PE ratio of 11.14 and an EV to EBITDA of 9.18. Despite recent stock performance showing a decline of 53.22% over the past year compared to a 7.99% increase in the Sensex, the current valuation metrics position Balaxi Pharma as an attractive investment opportunity moving forward.

How has been the historical performance of Balaxi Pharma?

Balaxi Pharma's historical performance shows fluctuating financial metrics, with net sales increasing to 292.56 Cr in March 2025 from 241.29 Cr in March 2024, but declining from 336.43 Cr in March 2023. Profit after tax also decreased to 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 2023.

Answer:<BR>The historical performance of Balaxi Pharma shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Balaxi Pharma's net sales reached 292.56 Cr in March 2025, an increase from 241.29 Cr in March 2024, but a decline from 336.43 Cr in March 2023. Total operating income mirrored this trend, with 292.56 Cr in March 2025 compared to 241.29 Cr in March 2024 and 336.43 Cr in March 2023. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, rising from 194.56 Cr in March 2024 but down from 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024 and 59.17 Cr in March 2023. Profit before tax also declined to 28.67 Cr in March 2025 from 40.31 Cr in March 2024 and 56.92 Cr in March 2023, leading to a profit after tax of 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 2023. The company's total assets increased to 310.34 Cr in March 2025 from 258.34 Cr in March 2024, while total liabilities also rose to 310.34 Cr in March 2025 from 258.34 Cr in March 2024. Cash flow from operating activities showed a negative trend, with -35.00 Cr in March 2025 compared to 4.00 Cr in March 2024, while cash and cash equivalents decreased to 39.00 Cr in March 2025 from 62.00 Cr in March 2024.

How has been the historical performance of Balaxi Pharma?

Balaxi Pharma's historical performance shows fluctuating net sales and profits, with net sales increasing to 292.56 Cr in March 2025 but profits declining, resulting in a profit after tax of 25.07 Cr. The company faces challenges in cash generation, as indicated by negative cash flow from operating activities.

Answer:<BR>The historical performance of Balaxi Pharma shows a fluctuating trend in net sales and profits over the years, with a notable increase in recent periods.<BR><BR>Breakdown:<BR>Balaxi Pharma's net sales reached 292.56 Cr in March 2025, up from 241.29 Cr in March 2024, but down from 336.43 Cr in March 2023. The total operating income followed a similar pattern, peaking at 336.43 Cr in March 2023 before declining to 292.56 Cr in March 2025. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, which was an increase from 194.56 Cr in March 2024 but lower than 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024, reflecting a declining operating profit margin of 12.72%. Profit before tax also saw a decline to 28.67 Cr in March 2025 from 40.31 Cr in March 2024, leading to a profit after tax of 25.07 Cr in March 2025, down from 35.91 Cr in March 2024. The company's total assets increased to 310.34 Cr in March 2025, up from 258.34 Cr in March 2024, while total liabilities also rose to 310.34 Cr from 258.34 Cr. Cash flow from operating activities turned negative at -35.00 Cr in March 2025, contrasting with a positive cash flow of 4.00 Cr in March 2024, indicating challenges in cash generation. Overall, Balaxi Pharma's financial performance reflects volatility with a recent trend of declining profits despite increased sales.

Who are the top shareholders of the Balaxi Pharma?

The top shareholders of Balaxi Pharma include Balaxi Overseas Private Limited with 63.4%, foreign institutional investors holding 16.02%, and Unico Global Opportunities Fund Limited as the largest public shareholder at 8.29%. Individual investors own 9.82%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Balaxi Pharma include the promoters, with Balaxi Overseas Private Limited holding the largest share at 63.4%. Additionally, foreign institutional investors (FIIs) collectively hold 16.02%, with three FIIs involved. The highest public shareholder is Unico Global Opportunities Fund Limited, which owns 8.29%. Individual investors account for 9.82% of the company's shares. There are no pledged promoter holdings, and no mutual funds currently hold shares in the company.

What is the technical trend for Balaxi Pharma?

As of April 21, 2025, Balaxi Pharma's technical trend has shifted to a moderate bearish stance, driven by bearish MACD, moving averages, and KST indicators, despite some divergence in the RSI and mildly bearish Bollinger Bands.

As of 21 April 2025, the technical trend for Balaxi Pharma has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on both weekly and monthly time frames, bearish moving averages on the daily chart, and a bearish KST on both weekly and monthly time frames. The RSI shows no signal on the weekly but is bullish on the monthly, indicating some divergence. Bollinger Bands are mildly bearish on both weekly and monthly charts, while the Dow Theory indicates a mildly bearish trend on the weekly and no trend on the monthly. Overall, the bearish signals dominate the current technical outlook.

When is the next results date for Balaxi Pharma?

No Upcoming Board Meetings

Has Balaxi Pharma declared dividend?

Balaxi Pharmaceuticals Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of July 1, 2022. Despite this, the company has experienced significant volatility, showing negative total returns in shorter periods, while the 5-year period reflects a positive return of 138.34%.

Balaxi Pharmaceuticals Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 01 Jul 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -38.66%, the dividend return was 0%, resulting in a total return of -38.66%.<BR><BR>For the 1-year period, the price return was -51.55%, the dividend return was 0%, leading to a total return of -51.55%.<BR><BR>Over the 2-year period, the price return was -51.61%, with a dividend return of 0%, culminating in a total return of -51.61%.<BR><BR>In the 3-year period, the price return was -37.85%, the dividend return was 0.68%, resulting in a total return of -37.17%.<BR><BR>For the 4-year period, the price return was -57.93%, the dividend return was 0.43%, leading to a total return of -57.5%.<BR><BR>In the 5-year period, the price return was 136.37%, with a dividend return of 1.97%, culminating in a total return of 138.34%.<BR><BR>Overall, Balaxi Pharmaceuticals Ltd has declared a dividend, but the total returns over the various periods indicate significant volatility, with negative returns dominating in the shorter time frames, while the 5-year period shows a substantial positive return.